Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathy...
- Autores
- Parisi, Muriel Solange; Oliveri, María Beatriz; Somoza, Julia Isabel; Mautalen, Carlos Alfredo
- Año de publicación
- 2003
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The efficacy and safety of the vitamin D analog, doxercalciferol (1α-hydroxyvitamin D2, 1αD2) in the treatment of secondary hyperparathyroidism in hemodialysis patients has been previously reported. We report thse effect of 16-week 1αD2 treatment on mineral metabolism and bone mineral density (BMD) in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy, resistant to previous calcitriol treatment. Levels of iPTH, bone-specific alkaline phosphatase and serum type I collagen C telopeptide were above normal at baseline and were substantially decreased with 1αD2 treatment (-92%, -63% and -53%, respectively). BMD increased in all areas: total skeleton (+6.5%), lumbar spine (+6.9%) and total femur (+4.3%). The patient showed no hypercalcemia, and phosphorus levels remained between 3.3 and 6.2 mg/dl.
Fil: Parisi, Muriel Solange. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina
Fil: Oliveri, María Beatriz. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina
Fil: Somoza, Julia Isabel. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina
Fil: Mautalen, Carlos Alfredo. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
BONE MINERAL DENSITY
BONE TURNOVER
DOXERCALCIFEROL
HEMODIALYSIS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/123716
Ver los metadatos del registro completo
id |
CONICETDig_461188c62fa744e7e4884b5544806101 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/123716 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomyParisi, Muriel SolangeOliveri, María BeatrizSomoza, Julia IsabelMautalen, Carlos AlfredoBONE MINERAL DENSITYBONE TURNOVERDOXERCALCIFEROLHEMODIALYSIShttps://purl.org/becyt/ford/3.5https://purl.org/becyt/ford/3The efficacy and safety of the vitamin D analog, doxercalciferol (1α-hydroxyvitamin D2, 1αD2) in the treatment of secondary hyperparathyroidism in hemodialysis patients has been previously reported. We report thse effect of 16-week 1αD2 treatment on mineral metabolism and bone mineral density (BMD) in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy, resistant to previous calcitriol treatment. Levels of iPTH, bone-specific alkaline phosphatase and serum type I collagen C telopeptide were above normal at baseline and were substantially decreased with 1αD2 treatment (-92%, -63% and -53%, respectively). BMD increased in all areas: total skeleton (+6.5%), lumbar spine (+6.9%) and total femur (+4.3%). The patient showed no hypercalcemia, and phosphorus levels remained between 3.3 and 6.2 mg/dl.Fil: Parisi, Muriel Solange. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; ArgentinaFil: Oliveri, María Beatriz. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; ArgentinaFil: Somoza, Julia Isabel. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; ArgentinaFil: Mautalen, Carlos Alfredo. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaDustri-verlag Dr Karl Feistle2003-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/123716Parisi, Muriel Solange; Oliveri, María Beatriz; Somoza, Julia Isabel; Mautalen, Carlos Alfredo; Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy; Dustri-verlag Dr Karl Feistle; Clinical Nephrology; 59; 6; 6-2003; 471-4740301-0430CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.5414/cnp59471info:eu-repo/semantics/altIdentifier/url/https://www.dustri.com/article_response_page.html?artId=336&doi=10.5414/CNP59471&L=0info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:00:18Zoai:ri.conicet.gov.ar:11336/123716instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:00:18.987CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy |
title |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy |
spellingShingle |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy Parisi, Muriel Solange BONE MINERAL DENSITY BONE TURNOVER DOXERCALCIFEROL HEMODIALYSIS |
title_short |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy |
title_full |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy |
title_fullStr |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy |
title_full_unstemmed |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy |
title_sort |
Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy |
dc.creator.none.fl_str_mv |
Parisi, Muriel Solange Oliveri, María Beatriz Somoza, Julia Isabel Mautalen, Carlos Alfredo |
author |
Parisi, Muriel Solange |
author_facet |
Parisi, Muriel Solange Oliveri, María Beatriz Somoza, Julia Isabel Mautalen, Carlos Alfredo |
author_role |
author |
author2 |
Oliveri, María Beatriz Somoza, Julia Isabel Mautalen, Carlos Alfredo |
author2_role |
author author author |
dc.subject.none.fl_str_mv |
BONE MINERAL DENSITY BONE TURNOVER DOXERCALCIFEROL HEMODIALYSIS |
topic |
BONE MINERAL DENSITY BONE TURNOVER DOXERCALCIFEROL HEMODIALYSIS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.5 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
The efficacy and safety of the vitamin D analog, doxercalciferol (1α-hydroxyvitamin D2, 1αD2) in the treatment of secondary hyperparathyroidism in hemodialysis patients has been previously reported. We report thse effect of 16-week 1αD2 treatment on mineral metabolism and bone mineral density (BMD) in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy, resistant to previous calcitriol treatment. Levels of iPTH, bone-specific alkaline phosphatase and serum type I collagen C telopeptide were above normal at baseline and were substantially decreased with 1αD2 treatment (-92%, -63% and -53%, respectively). BMD increased in all areas: total skeleton (+6.5%), lumbar spine (+6.9%) and total femur (+4.3%). The patient showed no hypercalcemia, and phosphorus levels remained between 3.3 and 6.2 mg/dl. Fil: Parisi, Muriel Solange. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina Fil: Oliveri, María Beatriz. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina Fil: Somoza, Julia Isabel. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina Fil: Mautalen, Carlos Alfredo. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín. División Osteopatías; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
description |
The efficacy and safety of the vitamin D analog, doxercalciferol (1α-hydroxyvitamin D2, 1αD2) in the treatment of secondary hyperparathyroidism in hemodialysis patients has been previously reported. We report thse effect of 16-week 1αD2 treatment on mineral metabolism and bone mineral density (BMD) in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy, resistant to previous calcitriol treatment. Levels of iPTH, bone-specific alkaline phosphatase and serum type I collagen C telopeptide were above normal at baseline and were substantially decreased with 1αD2 treatment (-92%, -63% and -53%, respectively). BMD increased in all areas: total skeleton (+6.5%), lumbar spine (+6.9%) and total femur (+4.3%). The patient showed no hypercalcemia, and phosphorus levels remained between 3.3 and 6.2 mg/dl. |
publishDate |
2003 |
dc.date.none.fl_str_mv |
2003-06 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/123716 Parisi, Muriel Solange; Oliveri, María Beatriz; Somoza, Julia Isabel; Mautalen, Carlos Alfredo; Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy; Dustri-verlag Dr Karl Feistle; Clinical Nephrology; 59; 6; 6-2003; 471-474 0301-0430 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/123716 |
identifier_str_mv |
Parisi, Muriel Solange; Oliveri, María Beatriz; Somoza, Julia Isabel; Mautalen, Carlos Alfredo; Effect of doxercalciferol (1α-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy; Dustri-verlag Dr Karl Feistle; Clinical Nephrology; 59; 6; 6-2003; 471-474 0301-0430 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.5414/cnp59471 info:eu-repo/semantics/altIdentifier/url/https://www.dustri.com/article_response_page.html?artId=336&doi=10.5414/CNP59471&L=0 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Dustri-verlag Dr Karl Feistle |
publisher.none.fl_str_mv |
Dustri-verlag Dr Karl Feistle |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269631118573568 |
score |
13.13397 |